PKHD1 Prenatal Sequence Analysis (GeneAware) (Prenatal Sequence Analysis) Baylor Genetics United States | 1 | 1 | - E Sequence analysis of select exons
|
Super Panel Plus NxGen MDx United States | 116 | 117 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Polycystic Kidney Disease GeneDx United States | 5 | 7 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|
Super Panel 113 NxGen MDx United States | 113 | 115 | - D Deletion/duplication analysis
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 14 Natera, Inc. United States | 15 | 15 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 plus TSE Natera, Inc. United States | 103 | 107 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 Natera, Inc. United States | 28 | 28 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 106 Natera, Inc. United States | 103 | 106 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 27 plus TSE Natera, Inc. United States | 28 | 29 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Plus TSE Natera, Inc. United States | 265 | 275 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc. United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 plus TSE Natera, Inc. United States | 135 | 138 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 137 Natera, Inc. United States | 135 | 137 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 274 Natera, Inc. United States | 265 | 274 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 14 plus TSE Natera, Inc. United States | 15 | 16 | - E Enzyme assay
- E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Horizon 14 Natera, Inc. United States | 15 | 15 | - E Sequence analysis of select exons
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
Polycystic Kidney Disease Asper Biogene Asper Biogene LLC Estonia | 38 | 23 | - C Sequence analysis of the entire coding region
|
Ciliopathies Asper Biogene Asper Biogene LLC Estonia | 166 | 120 | - C Sequence analysis of the entire coding region
|
Foresight Myriad Genetics, Inc. United States | 112 | 110 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
- T Targeted variant analysis
|
PKHD1 Sequencing and Deletion/Duplication Analysis DDC Clinic Molecular Diagnostics Laboratory DDC Clinic, Center for Special Needs Children United States | 1 | 1 | - D Deletion/duplication analysis
- C Sequence analysis of the entire coding region
|